- Home
- EXEL
EXEL
Exelixis Inc.
as 12-17-2024 4:00pm EST
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | ALAMEDA |
| Market Cap: | 10.0B | IPO Year: | 2000 |
| Target Price: | $32.18 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.55 | EPS Growth: | 441.02 |
| 52 Week Low/High: | $19.20 - $36.97 | Next Earning Date: | 02-04-2025 |
| Revenue: | $2,081,598,000 | Revenue Growth: | 17.31% |
| Revenue Growth (this year): | 20.59% | Revenue Growth (next year): | 1.50% |
Stock Insider Trading Activity of Exelixis Inc. (EXEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hessekiel Jeffrey | EXEL | EVP & General Counsel | Nov 27 '24 | Sell | $36.67 | 60,000 | $2,200,200.00 | 486,059 | |
| Haley Patrick J. | EXEL | EVP, Commercial | Nov 22 '24 | Sell | $35.27 | 10,000 | $352,700.00 | 278,665 | |
| Haley Patrick J. | EXEL | EVP, Commercial | Nov 15 '24 | Sell | $34.36 | 41,588 | $1,428,822.38 | 278,665 | |
| Aftab Dana | EXEL | CSO/EVP Disc & Trans Research | Nov 5 '24 | Sell | $35.00 | 96,986 | $3,394,510.00 | 498,945 | |
| Hessekiel Jeffrey | EXEL | EVP & General Counsel | Nov 1 '24 | Sell | $34.13 | 50,000 | $1,706,500.00 | 486,059 | |
| POSTE GEORGE | EXEL | Director | Nov 1 '24 | Sell | $34.00 | 30,000 | $1,020,000.00 | 169,020 | |
| Aftab Dana | EXEL | CSO/EVP Disc & Trans Research | Oct 30 '24 | Sell | $31.40 | 1,162 | $36,486.80 | 498,945 | |
| Hessekiel Jeffrey | EXEL | EVP & General Counsel | Oct 28 '24 | Sell | $28.39 | 25,000 | $709,750.00 | 486,059 | |
| Hessekiel Jeffrey | EXEL | EVP & General Counsel | Sep 23 '24 | Sell | $26.38 | 25,000 | $659,500.00 | 486,059 |
Latest Exelixis Inc. News
EXEL Breaking Stock News: Dive into EXEL Ticker-Specific Updates for Smart Investing
MT Newswires
20 hours ago
Exelixis Risk/Reward Now 'More Balanced' With 2025 Catalysts Priced In, BofA Says
MT Newswires
a day ago
BofA Securities Downgrades Exelixis to Neutral, $39 Price Target
Zacks
6 days ago
SpringWorks Therapeutics (SWTX) Up 14.5% Since Last Earnings Report: Can It Continue?
Zacks
7 days ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Argus Research
8 days ago
EXEL: Rating decreased to a HOLD
Zacks
9 days ago
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
Zacks
9 days ago
EXEL or INCY: Which Is the Better Value Stock Right Now?
Zacks
9 days ago
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag
Compare EXEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EXEL Exelixis Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.